Key Highlights

  • OncoVista filed a Form 15-12G in 2016 to deregister and cease its SEC reporting obligations, marking its shift to a non-reporting shell.
  • Its last Annual Report on file covered fiscal 2014, and its last Quarterly Report covered a 2015 period.
  • The company was once a San Antonio-based clinical-stage pharmaceutical developer with ambitions in oncology.
  • OVIT trades near $0.0001 with a Market Capitalisation in the low single-thousands of dollars in the last closing session.

OncoVista Innovative Therapies, Inc. (OTC:OVIT) is one of those names that lingers on quote screens long after the working company behind it has gone quiet. Once a San Antonio-based clinical-stage pharmaceutical developer with ambitions in oncology, OncoVista today trades as a sub-penny shell, priced at a fraction of a cent with a Market Value measured in the low thousands of dollars.

Company and Latest Development

OncoVista was incorporated with a focus on developing anticancer therapeutics, and it built out a public filing history that stretched from the late 2000s through the mid-2010s. According to SEC EDGAR, the entity filed quarterly and annual reports for several years before that cadence stopped.

Its last annual report on file covered fiscal 2014, its last quarterly report covered a 2015 period, and the company subsequently filed a Form 15-12G in 2016 to deregister and cease its SEC reporting obligations. That deregistration marks OncoVista's transition from a reporting micro-cap to a dormant, non-reporting shell.

What Is Driving Attention Around OVIT?

There is no identifiable public catalyst behind any recent movement in OVIT. At a quoted price near $0.0001, the stock sits in territory where even nominal trading activity can register as large percentage swings, and where there is no fresh, verifiable company news to anchor a narrative.

Investors encountering OVIT should recognise that attention here is a function of its penny-stock status and its residual ticker, not of disclosed operational progress.

Key Numbers and Company Position

Verified figures are sparse by design once a company deregisters. Market data list OVIT near $0.0001 with a market capitalisation in the low single-thousands of dollars and no analyst coverage, figures consistent with a defunct or dormant shell.

Because OncoVista stopped filing financial statements after its mid-2010s reports, there is no current, audited picture of cash, revenue, or liabilities. The absence of recent filings is itself the key data point.

What Could Come Next?

For non-reporting shells, the realistic catalysts are corporate rather than clinical: a change of control, a Reverse merger that repurposes the ticker, a name change, or a formal move to revive reporting status. None of these is announced or confirmed for OncoVista.

Any genuine development would typically surface first through a new SEC filing or an OTC Markets disclosure.

Risks to Watch

The risks are as stark as they come in the Equity market. Sub-penny, non-reporting stocks carry extreme liquidity risk, wide bid-ask spreads, minimal transparency, and a high probability of total loss.

Without current financial disclosure, valuation is essentially guesswork, and such tickers are frequently targets of promotional activity.

Ten Years Without a Reporting Obligation

OncoVista Innovative Therapies is best understood not as an emerging oncology story but as a deregistered, sub-penny shell whose active reporting life ended years ago. With no verifiable catalyst, no current financials, and a Form 15 deregistration on the public record, the most useful thing investors can monitor is the SEC EDGAR and OTC disclosure record itself.

Until a concrete, filed development appears, OVIT remains a dormant ticker rather than an operating business.